tbuckley/cabot-search huggingface dataset:
SP0033 Improving The Screening and Management of Comorbidities in Rheumatic Diseases
Authors: Y. Van Eijk-Hustings
Journal: Annals of the Rheumatic Diseases (2016)

Research has shown that comorbidities, one or more additional disorders (or diseases) co-occurring with the primary disease, occur more frequently in patients with chronic inflammatory rheumatic diseases than in the general population, and are sub-optimally prevented, screened for and managed. In order to contribute to improvement, a EULAR task force has developed points to consider for reporting, screening and preventing selected comorbidities in daily practice. The points to consider and the results from the literature that supported their development have been presented at the EULAR conference in Rome in 2015 and have recently been accepted for publication in ARD. In accordance with the EULAR Standardized Operating Procedures, a multidisciplinary task force from 12 different countries selected six comorbidities (ischemic cardiovascular diseases, malignancies, infections, peptic ulcer, osteoporosis, depression), based on their frequency and severity (e.g. their impact on mortality and disease outcomes) in a first meeting. Results from a systematic literature review of existing recommendations or guidelines on the reporting, screening, or prevention for each of the selected comorbidities guided the second meeting of the task force. In this consensus meeting a reporting form, an extensive list of variables to be collected in order to report history/occurrence of the comorbidity and current treatments, risk factors and screening, or prevention, was decided on. Standardization of the screening for and reporting of comorbidities will enhance implementation across Europe. The role of patients in the management of their own disease, including the screening for comorbidities, is increasing. Facilitating patients9 involvement in their own care requires various activities. Regarding comorbidities, awareness about the points to consider by developing and disseminating a lay version is necessary but is not sufficient. Tools such as self-administered questionnaires and supporting information can help strategic implementation of the points to consider, particularly if they are supported with further explanation to the patient whilst empowering them to become more actively engaged in comorbidity self-management. Tools however, also need to make sense to the patient, and should be easily administered and results should be easily interpreted. Also, follow-up of results should be clear. In what way such a tool can be integrated in daily care, what educational materials for patients are necessary, and how concerns for comorbidities can be reduced needs further exploration. <h3>Disclosure of Interest</h3> None declared
The long term outcome of the patients with chronic myeloid leukemia (CML) who have achieved complete cytogenetic response (CCgR) to interferon-alpha (IFN alpha). A collaborative European study of 317 cases.
Authors: F Bonifazi, A De Vivo, G Rosti, F Guilhot, J Guilhot, E Trabacchi, R Hehlmann, A Hochhaus, P Shepherd, JL Steegmann, Johanna Kluin-Nelemans, J Thaler, B Simonsson, A Louwagie, J Reiffers, FX Mahon, E Montefusco, G Alimena, J Hasford, S Richards, G Saglio, N Testoni, G Martinelli, S Tura, M Baccarani
Journal: Blood (2001)
Trisomy of Chromosome 7: a Novel Cytogenetic Abnormality in a Paediatric Case of Mixed Acute Leukemia.
Authors: Rosanna Parasole, Laura Vicari, Fara Petruzziello, Anna Leszl, Giuseppe Menna, M. Tarsitano, Luigi Del Vecchio, Giulia Scalia, Giovanna Maisto, Giuseppe Basso, Vincenzo Poggi, Nicoletta Marra
Journal: Blood (2009)
Subcutaneous Omacetaxine (OM) Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients Following Multiple Tyrosine Kinase Inhibitor (TKI) Failure
Authors: Jorge E. Cortes, Meir Wetzler, Jeff Lipton, Franck E Nicolini, Michele Baccarani, Maria R Baer, H. Jean Khoury, David Cram, Eric D. Humphriss, Annie-Claude Benichou, Adam Craig, Hagop M. Kantarjian
Journal: Blood (2010)
Lipid Disorders: Screening and Treatment
Authors: Jill Jin
Journal: JAMA (2016)

US Preventive Services Task Force; Kirsten Bibbins-Domingo, PhD, MD, MAS; David C. Grossman, MD, MPH; Susan J. Curry, PhD; Karina W. Davidson, PhD, MASc; John W. Epling Jr, MD, MSEd; Francisco A. R. García, MD, MPH; Matthew W. Gillman, MD, SM; Alex R. Kemper, MD, MPH, MS; Alex H. Krist, MD, MPH; Ann E. Kurth, PhD, RN, MSN, MPH; C. Seth Landefeld, MD; Michael L. LeFevre, MD, MSPH; Carol M. Mangione, MD, MSPH; William R. Phillips, MD, MPH; Douglas K. Owens, MD, MS; Maureen G. Phipps, MD, MPH; Michael P. Pignone, MD, MPH
Long-Term Efficacy and Safety Results From a Phase II Study of Ruxolitinib in Patients with Polycythemia Vera
Authors: Srdan Verstovsek, Francesco Passamonti, Alessandro Rambaldi, Giovanni Barosi, Peter J. Rosen, Shui He, Nancy Contel, Bijoyesh Mookerjee, Elisa Rumi, Elisabetta Gattoni, Lisa Pieri, Mario Cazzola, Hagop M. Kantarjian, Tiziano Barbui, Alessandro M. Vannucchi
Journal: Blood (2012)
INTRAVENOUS DILTIAZEM IN PATIENTS WITH UNSTABLE ANGINA - A RANDOMIZED, DOUBLE-BLIND COMPARISON WITH NITROGLYCERIN - 1ST RESULTS
Authors: Ej Gobel, Jn Spanjaard, Rw Hautvast, Hl Hillege, Mj Dejongste, Gp Molhoek, Wh Vangilst
Journal: Circulation (1994)
Вплив функціонального стану жовчного міхура на особливості ліпідного обміну в дітей зі стеатозом печінки
Authors: Y.M. Stepanov, N.Y. Zavgorodnya, S.O. Babiy, I.A. Klenina
Journal: GASTROENTEROLOGY (2016)

Мета. Вивчити особливості ліпідного обміну в дітей зі стеатозом печінки залежно від функціонального стану жовчного міхура. Матеріали і методи дослідження. Під спостереженням перебувала 31 дитина віком від 10 до 17 років. Пацієнти сформували 4 групи: І група — 8 дітей з нормокінезією жовчного міхура без стеатозу печінки, яку обрано як групу порівняння; ІІ група — 11 дітей з гіпокінезією жовчного міхура без стеатозу печінки; ІІІ група — 6 дітей з нормокінезією жовчного міхура і стеатозом печінки; IV група — 6 дітей з гіпокінезією жовчного міхура зі стеатозом печінки. Як дослідні маркери ліпідного спектру сироватки крові використано вміст загального холестерину, тригліцеридів, ліпопротеїнів високої щільності, ліпопротеїнів низької щільності, ліпопротеїнів дуже низької щільності й розраховано коефіцієнт атерогенності. Результати. Вивчено особливості ліпідного спектра крові при стеатозі печінки в дітей залежно від функціонального стану жовчного міхура. Показано, що найпоширенішими фенотипами дисліпопротеїнемій серед обстежених дітей були ізольована гіперхолестеринемія з дисліпопротеїнемією ІІа типу і комбінована гіперліпідемія з дисліпопротеїнемією ІІb типу. Виявлено, що характерною для дітей зі стеатозом і гіпокінезією жовчного міхура є дисліпідемія, яка проявляється у зростанні в сироватці крові вмісту загального холестерину, ліпопротеїнів низької щільності і коефіцієнту атерогенності. Серед пацієнтів зі стеатозом відмічався високий відсоток дітей, у яких визначено вірогідне зниження в сироватці крові вмісту холестерину ліпопротеїнів високої щільності і холестерину ліпопротеїнів дуже низької щільності, що призводило до посилення атерогенних властивостей крові при нормальному рівні всіх інших ліпідних фракцій. Наукова новизна. Висловлено припущення про існування різних шляхів формування стеатозу печінки в дітей з нормокінезією та гіпокінезією жовчного міхура, підґрунтям яких є порушення жовчоутворення й жовчовиведення. Практична значимість. Запропоновано проведення постійного контролю рівня загального холестерину, холестерину ліпопротеїнів високої щільності й холестерину ліпопротеїнів дуже низької щільності як додаткових маркерів для раннього виявлення розладів ліпідного обміну в дітей з функціональними порушеннями біліарного тракту за гіпокінетичним типом.
Whole Genome Sequencing of Indolent CLL Reveals Novel Structural Rearrangements
Authors: Siddha Kasar, Grace Tiao, Reina Improgo, Adam Kiezun, Carrie Sougnez, Samira Bahl, Stacey M. Fernandes, Alexander R. Vartanov, Kevin Hoang, Stacey Gabriel, Dan A. Landau, Catherine J Wu, Eric Lander, Haesook T. Kim, Gad Getz, Jennifer R. Brown
Journal: Blood (2014)
Humanized Sc(Fv)2 Minibody against C-Mpl Successfully Increased Platelet Number in Monkey and Increased Engraftment of Human Umbilical Cord Blood Cells in NOD/SCID Mouse.
Authors: Takashi Yoshikubo, Yoshihiro Matsumoto, Masahiko Nanami, Takayuki Sakurai, Hiroyuki Tsunoda, Akihisa Kaneko, Yukiko Inagaki, Masashi Shiina, Mizuho Noguchi, Makoto Monnai, Souhei Ohyama, Yukihito Miura, Tetsuro Orita, Yasufumi Kikuchi, Tomoyuki Igawa, Kunihiro Hattori, Hisafumi Okabe
Journal: Blood (2008)
Increased Serum Transforming Growth Factor-beta1 (Tgf-beta1) Is Related to a Better Outcome in MM, WM and CLL Patients
Authors: Dimitrios Maltezas, Katerina Sarris, Efstathios Koulieris, Tatiana Tzenou, Vassiliki Bartzis, Eftychia Nikolaou, Maria Gavriatopoulou, Maria Dimou, Evangelos Terpos, Maria K. Angelopoulou, Theodoros P. Vassilakopoulos, Panayiotis Panayiotidis, Gerasimos Pangalis, Meletios A Dimopoulos, Marie-Christine Kyrtsonis
Journal: Blood (2012)
PWE-108 Feasibility, Safety and Efficacy of Knife Assisted Resection (KAR) of Rectal Polyps Extending to The Dentate Line: How Low Can You Go?: Abstract PWE-108 Table 1
Authors: K Kandiah, FJQ Chedgy, S Thayalasekaran, S Subramaniam, R Bhattacharyya, F Thursby-Pelham, P Bhandari
Journal: Gut (2016)

<h3>Introduction</h3> Rectal polyps extending to the dentate line (RPDL) pose a technical challenge to endoscopic resection due to the narrow lumen, rich venous/haemorrhoidal plexus and proximity to the skin. Conventional snare EMR is challenging due to the restrcited space and lack of precision with the snare. This has led to the use of surgical techniques like TEMS and TAR for resection of RPDLs. <b>K</b>nife <b>A</b>ssisted snare <b>R</b>esection (KAR) allows for precise mucosal incision at the dentate line and the dissection of the polyp from the anorectal junction. We aim to assess the feasibility, safety and efficacy of KAR for RPDLs. <h3>Methods</h3> This is a prospective observational study of patients who underwent KAR with a mean follow up of 32 months (range 1–83 months). All procedures were done on a day case basis and were carried out under sedation by two endoscopists using high definition gastroscopes with a distal transparent cap. The polyp margin on the anal side was injected with lifting solution consisting of gelofusin, indigo carmine, 1% lignocaine and adrenaline. Haemostasis was maintained using a combination of the endoscopic knife and coag-grasper (Olympus Medical). A mucosal incision was extended around the margins of the polyp, followed by submucosal dissection to facilitate snare deployment to achieve complete polyp resection. Post-procedural antibiotics were not routinely given. <h3>Results</h3> A total of forty patients (20 female, median age 69 years) underwent KAR for RPDLs over the study period. The polyp characteristics and histology are described in Table 1. The curative resection after a single KAR was achieved in 33 (82.5%) patients. 7 of the 40 patients required further KARs, leading to a total curative resection rate to 97%. The risk factors for multiple resections are polyps measuring &gt;60 mm and encompassing &gt;50% of the circumference (p &lt; 0.01). Overall, there was one complication where the patient had delayed bleeding which was managed conservatively. None of the patients experienced perforation, or post-procedural sepsis. <h3>Conclusion</h3> This is the largest reported series of KAR for RPDLs. Our data demonstrates that for Western endoscopists, KAR is a very safe and effective technique in the treatment of RPDLs. As KAR is a viable alternative to full ESD, TEMS and TAR, it will play an increasingly significant role in the management of RPDLs. <h3>Disclosure of Interest</h3> None Declared
A New Human CD20 Antibody for Improved Killing of CD20-Transgenic T Cells for Allogeneic Stem Cell Transplantation.
Authors: Tom van Meerten, Wendy J.M. Mackus, Paul W.H.I. Parren, Jan G.J. van de Winkel, Anton Hagenbeek, Saskia B. Ebeling
Journal: Blood (2005)
Active Site-Inactivated Recombinant Factor VIIa Blocks Shiga Toxin-Induced Upregulation of Tissue Factor Activity on Human Glomerular Endothelial Cells and Human Proximal Tubular Epithelial Cells.
Authors: Eirini Nestoridi, Rafail Kushak, Julie R. Ingelfinger, Eric F. Grabowski
Journal: Blood (2004)
Low-Dose IL-2 Reduces Mitochondrial Priming and Increases Bcl2 Expression in CD4 Memory Regulatory T Cells
Authors: Kazuyuki Murase, Haesook T. Kim, Masahiro Hirakawa, Tiago Reis Matos, Yutaka Kawano, Jeremy Ryan, Ken-Ichi Matsuoka, John Koreth, Robert J Soiffer, Anthony G. Letai, Junji Kato, Jerome Ritz
Journal: Blood (2014)
Acute Renal Failure Is a Common Presentation of Engraftment Syndrome In Light Chain Amyloidosis (AL) Patients After Autologous Stem Cell transplantation.
Authors: Maria V Irazabal, Aflonso Eirin, Morie Abraham A. Gertz, Angela Dispenzieri, Shaji Kumar, Francis Buadi, Martha Lacy, Suzanne R. Hayman, David Dingli, William J Hogan, Nelson Leung
Journal: Blood (2010)
Baseline Peripheral Neuropathy Does Not Impact the Efficacy and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ): Results of a Subset Analysis of a Phase 2 Trial In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM)
Authors: Thomas Martin, Seema B. Singhal, Ravi Vij, Michael Wang, A. Keith Stewart, Sundar Jagannath, Sagar Lonial, Andrzej J Jakubowiak, Vishal Kukreti, Nizar J Bahlis, Melissa Alsina, Asher A. Chanan-Khan, George Somlo, Francis Buadi, Frederic J. Reu, Jeffrey A. Zonder, Kevin Song, Edward A. Stadtmauer, Alvin F. Wong, Marcy Vallone, Yu-Lin Chang, Michael Kauffman, Robert Z. Orlowski, David Samuel diCapua Siegel
Journal: Blood (2010)
Myelodysplastic Syndromes and Acute Myeloid Leukemia with t(6;9)(p23;q34).
Authors: John Delmonte, Hagop M. Kantarjian, Farhad Ravandi, Gautam Borthakur, Francis J. Giles, Lynne Abruzzo, Sherry Pierce, Jorge Cortes
Journal: Blood (2007)
The Addition of Bevacizumab to Standard Therapy with R-CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Is Associated with an Increased Rate of Cardiac Adverse Events: Final Analysis of Safety and Efficacy Outcomes From the Placebo-Controlled Phase 3 MAIN Study
Authors: John F. Seymour, Michael Pfreundshuh, B. Coiffier, Marek Trneny, Laurie H. Sehn, Eva Csinady
Journal: Blood (2012)
CD4 Treg and CD4 Tcon Utilize Distinct TCR Vbeta Repertoires in Response to Alloantigen
Authors: Anandharaman Veerapathran, Micheal Schell, Francisca Beato, TzuHua Juan, Sean Yoder, Brian C Betts, Joseph A Pidala, Claudio Anasetti
Journal: Blood (2015)
Cranial Irradiation Does Not Result in Pituitary-Gonadal Axis Dysfunction in Very Long-Term Male Survivors of Childhood Acute Lymphoblastic Leukemia.
Authors: Niels J. van Casteren, Rob Pieters, Gert Dohle, Manita van Baalen, Sebastian Neggers, M.M. Van Den Heuvel
Journal: Blood (2009)
The Dimerization Domain and C-Terminal NCoR/SMRT Interacting Zinc-Finger Domain of t(8;21) Fusion Protein AML1-ETO Have Critical and Opposite Effects on Leukemogenesis.
Authors: Ming Yan, Eiki Kanbe, Luke F. Peterson, Anita Boyapati, Robert Hines, Dong-Er Zhang
Journal: Blood (2004)
SP0010 Can We Change Perceptions on The Use of Glucocorticoids?
Authors: M. de Wit
Journal: Annals of the Rheumatic Diseases (2016)

Glucocorticoids have a bad reputation. not only among patients but also among health professionals and the general public. It makes that the same scientific data can be interpreted differently and leads to recommendations that are seen as arbitrary. The lack of consensus confuses patients who receive different messages when prednisolon is prescribed and it hampers an effective implementation of recommendations in clinical practice. The result is that patients are not optimally informed and educated about the real benefits and risks of the treatment. It can lead to non-adherence, under-treatment, over-treatment, the use of expensive medicines and ultimately to suboptimal disease outcomes. With the new EULAR consensus document the first hurdle of controversial recommendations has been tackled. This document paves the way to a better education of patients, health professionals and general public. However, the key messages are difficult to understand and require an effort of all involved to develop an innovative approach to communicate the complex interplay between disease activity and the benefits and risks of glucocorticoid use to patients. The first step is to disseminate the recommendations in a tailored manner to the different audiences. Patients require other kinds of information and provided in other formats than health professionals or the general public. Examples will be presented during this session. <h3>Disclosure of Interest</h3> None declared
PTH-011 Novel Endoscopic Ultrasound-Guided Interventional Techniques for The Palliative Management of Malignant Biliary Tract Obstruction: A Single UK Centre Experience
Authors: B Paranandi, KW Oppong, J Rammell, JJ French, C Wilson, M Dawwas, MK Nayar
Journal: Gut (2016)

<h3>Introduction</h3> Endoscopic retrograde cholangiopancreatography (ERCP) is used as the first-line modality for biliary drainage in patients with obstructive jaundice. However, anatomical or technical factors may preclude conventional trans-papillary biliary access in less than 10% of cases. Endoscopic ultrasound-guided biliary drainage (EUS-BD) has recently emerged as an alternative method to percutaneous transhepatic biliary drainage (PTBD) or surgical biliary bypass after unsuccessful ERCP in patients with inoperable pancreatobiliary malignancies. We present initial experience of EUS-BD in our unit. <h3>Methods</h3> A prospectively collected database, of consecutive patients undergoing EUS-BD in our unit, was analysed. Data was retrieved from electronic, clinical and endoscopy records. All EUS-BD procedures were undertaken in the endoscopy department, under conscious sedation, using Pentax echoendoscopes and Hitachi ultrasound workstations. In all cases, conventional diagnostic EUS procedure was performed followed by trans-luminal EUS-guided placement of metal stents. One of three endoscopists (KO/MN/MD) performed the procedures. The primary outcome measurements were technical success, clinical success and adverse events. <h3>Results</h3> 4 EUS-BD procedures were performed in 4 patients – ¾ were female (75%) with median age 70 years (range 51–79). The primary indication in all patients was malignant biliary obstruction, which was not amenable to either PTBD or surgery. One patient had symptomatic cystic duct obstruction with gallbladder empyema. 1 patient received a Hot AXIOS™ covered lumen apposing metal stent (cLAMS), 1 had a Wallflex™ biliary fully covered self-expanding metal stent (fcSEMS) and the others had NAGI™ covered self-expanding metal stents (cSEMS) inserted. Technical and clinical success was 100% across all procedures with symptomatic improvement noted in all patients. Serum bilirubin measurements decremented post EUS-BD by median 89% (range 85–98%). No procedure related complications were seen. During follow up, 3/4 patients have died (median 7 months (range 3–8) from date of EUS-BD) of end-stage disease (unrelated to the EUS-BD procedure). The 4<sup>th</sup> patient remains clinically stable on follow-up (2 months after EUS-BD) with no evidence of further biliary symptoms. <h3>Conclusion</h3> Our early experience of EUS-BD confirms that it is a safe and effective palliative procedure in patients with malignant biliary tract obstruction, in whom surgery and/or PTBD are less favourable. We recommend that EUS-BD is performed after multidisciplinary team discussion and by experienced therapeutic endosonographers. <h3>Disclosure of Interest</h3> None Declared
SP0118 The Ongoing Shift of Paradigms within Physiotherapy and Pain Management
Authors: P. Åsenlöf
Journal: Annals of the Rheumatic Diseases (2016)

During the past three decades the search for effective non-pharmacological pain management methods in chronic non-cancer pain conditions has been intensified. However, despite a growing body of scientific studies, there is still no cure for chronic pain, and treatments targeting pain per se do not report sufficient effects in terms or pain relief. This lecture presents some important changes in foci regarding pain management in general and physiotherapy in particular. These are: (1) <i>From</i> problem-identification <i>to</i> goal attainment, (2) <i>From</i> pain intensity <i>to</i> activity interference, (3) <i>From</i> pain relief <i>to</i> behavioural skills training. The perspectives will be described and illustrated by scientific studies underpinning this development. Implications for pain management in inflammatory diseases and physiotherapy will be discussed with the audience. <h3>Disclosure of Interest</h3> None declared
The emerging role of ECM crosslinking in T cell mobility as a hallmark of immunosenescence in humans
Authors: Jean-Francois Moreau, Thomas Pradeu, Andrea Grignolio, Christine Nardini, Filippo Castiglione, Paolo Tieri, Miriam Capri, Stefano Salvioli, Jean-Luc Taupin, Paolo Garagnani, Claudio Franceschi
Journal: Ageing Research Reviews (2016)

Immunosenescence is thought to result from cellular aging and to reflect exposure to environmental stressors and antigens, including cytomegalovirus (CMV). However, not all of the features of immunosenescence are consistent with this view, and this has led to the emergence of the sister theory of "inflammaging". The recently discovered diffuse tissue distribution of resident memory T cells (TRM) which don't recirculate, calls these theories into question. These cells account for most T cells residing in barrier epithelia which sit in and travel through the extracellular matrix (ECM). With almost all studies to date carried out on peripheral blood, the age-related changes of the ECM and their consequences for T cell mobility, which is crucial for the function of these cells, have been largely ignored. We propose an update of the theoretical framework of immunosenescence, based on a novel hypothesis: the increasing stiffness and cross-linking of the senescent ECM lead to a progressive immunodeficiency due to an age-related decrease in T cell mobility and eventually the death of these cells. A key element of this mechanism is the mechanical stress to which the cell cytoplasm and nucleus are subjected during passage through the ECM. This hypothesis is based on an "evo-devo" perspective bringing together some major characteristics of aging, to create a single interpretive framework for immunosenescence.
Clinical Observation of Combination Therapy of Anti-Thymocyte Globulin Cyclosporine A, Hemopoietic Growth Factor and Androgen for 47 Severe Aplastic Anaemia Cases.
Authors: JianPing Shen, YuHong Zhou, Zhiying Zheng, Junfa Chen, Shengyun Lin, YiPing Shen, ZhiPing Hu, Xiusu Luo, BaoDong Ye, LongXi Yu
Journal: Blood (2006)